The GSK3A Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of Homo sapiens A-549 lung epithelial cells designed to disrupt the GSK3A gene. This polyclonal knockout pool provides a mixed population of loss-of-function variants, enabling robust functional studies without the clonal bias often associated with single-cell-derived lines. The product serves as a versatile tool for investigating GSK3A-dependent signaling mechanisms in lung adenocarcinoma cell models, supporting applications that require a representative spectrum of editing outcomes.
The A-549 cell line is a well-established model of lung adenocarcinoma, originally isolated from a 58-year-old male patient. These adherent epithelial cells retain characteristics of alveolar basal epithelium and are extensively employed for studying non-small cell lung cancer (NSCLC) biology, including signaling pathways driving proliferation, migration, and therapeutic resistance. Their robust growth and well-characterized transcriptome make them an ideal background for genetic perturbation, enabling dissection of tumor cell-intrinsic molecular networks.
GSK3A is a constitutively active serine/threonine kinase that acts as a central negative regulator of canonical Wnt/??-catenin signaling. Under basal conditions, GSK3A, in complex with AXIN1 and APC, phosphorylates CTNNB1 (??-catenin), targeting it for proteasomal degradation. Wnt stimulation through WNT3A-FZD-LRP receptors leads to disassembly of the destruction complex and GSK3A inactivation, allowing ??-catenin nuclear accumulation and TCF/LEF-mediated transcription of targets such as CCND1 (cyclin D1) and MYC. Additionally, GSK3A is regulated by insulin and growth factors via the PI3K/AKT pathway, wherein AKT1-mediated inhibitory phosphorylation modulates its activity toward glycogen synthase 1 (GYS1) and other metabolic effectors. The kinase also interacts with p53 and PP2A, linking its function to cell cycle control and apoptosis.
In the A-549 lung adenocarcinoma context, disruption of GSK3A provides a unique opportunity to parse its contributions to Wnt-driven oncogenesis independent of the GSK3B paralog. Given the frequent dysregulation of Wnt/??-catenin signaling in NSCLC, this polyclonal knockout model allows researchers to examine how loss of GSK3A influences ??-catenin stability, target gene expression, and cellular phenotypes such as proliferation and apoptosis. It also enables the investigation of potential crosstalk with insulin and PI3K/AKT pathways, which are often co-altered in lung cancer. The polyclonal nature of the knockout population reduces the risk of clonal artifact, making it suitable for pooled functional genomics studies and drug response profiling.
This product is ideal for detailed analysis of GSK3A-mediated signal transduction, including assessment of GSK3A phosphorylation status by Western blotting, ??-catenin localization by immunofluorescence, and TCF/LEF reporter activity using TOPFlash/FOPFlash luciferase assays. Transcriptional readouts of Wnt target genes (e.g., CCND1, MYC) can be quantified by RT-qPCR, while cellular outcomes such as viability, proliferation, and apoptosis are measurable via MTS, BrdU, and Annexin V assays, respectively. Moreover, the polyclonal knockout cells serve as a robust system for comparative studies between GSK3A and GSK3B isoforms, screening of isoform-selective inhibitors, and validation of chemical probes targeting the Wnt pathway. For customized services or additional information, please contact Ascent Research.
